drugset
drugset / Trial / NCT06022289

Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors

NCT06022289 ↗

Phase 2 Unknown 20 enrolled Tianjin Medical University Second Hospital
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this clinical trial is to demonstrate safety and efficacy of Pemigatinib in the treatment of advanced pan solid tumor patients with FGF/FGFR alterations.

Timeline

Start
2023-05-01
Primary completion
2025-05-01
Completion
2025-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Pemigatinib Small molecule 13.5 mg Oral

Indications

cancer